ICU: the cash flow

MyFinsight

For the year ending 2025-12-31, ICU had $10,161K increase in cash & cash equivalents over the period.

Cash Flow	2025-12-31
Net loss	-12,150
Amortization of deferred financing costs	18
Change in fair value of convertible notes (issued, converted and outstanding)	0
Change in fair value of liability classified warrants (exercised and outstanding)	-32
Shares issued for the standby equity purchase agreement commitment fee	298
Stock-based compensation	624
Accounts receivables, net	125
Inventory	66
Prepaid expenses	-538
Other assets	-314
Accounts payable	-2,098
Accrued expenses	-920
Other liabilities	0
Net cash used in operating activities	-13,599
Proceeds from issuance of convertible notes	0
Payment of convertible notes	0
Proceeds from issuance of shares, net of offering costs	16,126
Proceeds from exercise of warrants	1,815
Proceeds from pre-funded warrants	5,886
Proceeds from issuance of notes payable	767
Payment of notes payable	834
Net cash provided by financing activities	23,760
Net increase in cash	10,161
Cash, beginning of year	1,819
Cash, end of year	11,980

Unit: Thousand (K) dollars (except for numbers of shares and EPS).